Dynavax 
Welcome,         Profile    Billing    Logout  
 16 Products   6 Diseases  16 Products   27 Trials   1748 News 
66 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
DV 1179 / Dynavax
DV1179a: Dynavax Reports Second Quarter 2014 Financial Results and Safety and Pharmacodynamic Results for Asthma and Lupus Drug Candidates

Checkmark
Aug 2014 - Aug 2014: 
Not yet recruiting
1b/2a
52
RoW
DV 1179
Dynavax
Lupus
 
 
300002: Proof-of-mechanism clinical trial of the TLR7 and TLR9 inhibitor, DV1179

Recruiting
1
0
RoW
DV 1179
Dynavax Technologies Corporation
systemic lupus erythematosus
 
 
Heplisav-B (hepatitis B vaccine (recombinant), adjuvanted) / Dynavax
NCT04588077 / 2020-001766-11: Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis

Recruiting
4
200
US
Heplisav-B Injectable Product, 2-dose regimen, 2-dose regimen, Heplisav-B Injectable Product, 3-dose regimen, 3-dose regimen
Mercy Medical Center
Hepatitis B, Cirrhosis, Liver, Chronic Liver Disease
07/24
07/24
NCT05170399: Vaccine Responses in Patients With B Cell Malignancies

Recruiting
4
500
US
Fluzone, Shingrix, Flucelvax, Afluria, PREVNAR 13, Heplisav -B, Pfizer-COVID-19 Vaccine, FluLaval, Fluarix, PNEUMOVAX 23, PREVNAR 20, AREXVY, ABRYSVO
National Heart, Lung, and Blood Institute (NHLBI)
Lymphoma
08/25
08/25
BEe-HIVe, NCT04193189: B-Enhancement of HBV Vaccination in Persons Living With HIV (): Evaluation of HEPLISAV-B

Completed
3
640
US, RoW
HEPLISAV-B, ENGERIX-B
National Institute of Allergy and Infectious Diseases (NIAID), Dynavax Technologies Corporation
HIV Infection, Hepatitis B
08/24
08/24
TherVacB, NCT06513286: - A Heterologous Protein Prime/MVA Boost Therapeutic Hepatitis B Vaccine Candidate

Not yet recruiting
1/2
89
Europe
TherVacB (HEPLISAV B), TherVacB (HBsAg ± c-di-AMP)
Michael Hoelscher, Institute of Virology Helmholtz Zentrum München Trogerstraße 30 81675 Munich, Germany
Chronic Hepatitis B
12/26
12/26
NCT03934736: HEPLISAV-B® in Adults With End-Stage Renal Disease (ESRD) Undergoing Hemodialysis

Completed
1
119
US
HEPLISAV-B®
Dynavax Technologies Corporation
End Stage Renal Disease on Hemodialysis (Diagnosis)
10/20
09/21
NCT05727267: A Heterologous Protein Prime/MVA Boost Therapeutic Hepatitis B Vaccine Candidate

Recruiting
1
24
Europe
HEPLISAV B; TherVacB, TherVacB
Universitätsklinikum Hamburg-Eppendorf, German Center for Infection Research, Medical Biometry and Epidemiology_- Universitätsklinikum Hamburg Eppendorf, Helmholtz Zentrum München, The Fraunhofer-Gesellschaft, Institute of Virology Helmholtz Zentrum München (HMGU), LMU Klinikum
Chronic Hepatitis B
02/26
06/26
HBR2, NCT05791851: Heplisav-B Revaccination for Hepatitis B Vaccine Nonresponders

Completed
N/A
31
US
University of Maryland, Baltimore, Baltimore Veterans Affairs Medical Center
HIV Infections, Hepatitis B, Vaccine Response Impaired
06/22
06/22
NCT03664648: DV2-HBV-27: Observational Pregnancy Registry

Active, not recruiting
N/A
300
US
HEPLISAV-B
Dynavax Technologies Corporation, PPD, Part of Thermo Fisher Scientific
Pregnant
09/24
12/24
nelitolimod (SD-101) / TriSalus Life Sci, UT MD Anderson Cancer Center
NCT03007732: Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT

Checkmark Initation of trial of pembrolizumab alone or in combination with SD-101 for metastatic prostate cancer
Jun 2017 - Jun 2017: Initation of trial of pembrolizumab alone or in combination with SD-101 for metastatic prostate cancer
Completed
2
23
US
Pembrolizumab, MK-3475, Keytruda, SD-101, Toll-like receptor 9, Leuprolide acetate, Intermittent androgen deprivation therapy, Abiraterone Acetate, Prednisone, Stereotactic Body Radiation Therapy, SBRT
David Oh, Prostate Cancer Foundation, Merck Sharp & Dohme LLC, TriSalus Life Sciences, Inc.
Prostatic Neoplasms
03/25
03/25
I-SPY 2, NCT01042379: I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

Hourglass Jan 2023 - Dec 2023 : From P2 I-SPY 2 trial for invasive breast cancer
Checkmark Presentation of data from I-SPY trial for HR+/HER2- and TNBC breast cancer at SABCS 2022
Dec 2022 - Dec 2022: Presentation of data from I-SPY trial for HR+/HER2- and TNBC breast cancer at SABCS 2022
Checkmark Data from trial evaluating T-DM1+pertuzumab in the adjuvant setting
Nov 2018 - Nov 2018: Data from trial evaluating T-DM1+pertuzumab in the adjuvant setting
More
Recruiting
2
5000
US
Standard Therapy, Paclitaxel (Taxol); Doxorubicin (Adriamycin), AMG 386 with or without Trastuzumab, AMG 386 (Trebananib); (Trastuzumab) Herceptin, AMG 479 (Ganitumab) plus Metformin, Ganitumab, MK-2206 with or without Trastuzumab, (Trastuzumab) Herceptin, AMG 386 and Trastuzumab, AMG 386 (Trebananib); Trastuzumab (Herceptin), T-DM1 and Pertuzumab, T-DM1 (Trastuzumab emtansine); Pertuzumab (Perjeta), Pertuzumab and Trastuzumab, Pertuzumab (Perjeta); Trastuzumab (Herceptin), Ganetespib, ABT-888, Veliparib, Neratinib, PLX3397, Pembrolizumab - 4 cycle, Talazoparib plus Irinotecan, Patritumab and Trastuzumab, Pembrolizumab - 8 cycle, SGN-LIV1A, Durvalumab plus Olaparib, SD-101 + Pembrolizumab, Tucatinib plus trastuzumab and pertuzumab, Cemiplimab, Cemiplimab plus REGN3767, Trilaciclib with or without trastuzumab + pertuzumab, Trilaciclib (G1T28); Pertuzumab (Perjeta); Trastuzumab (Herceptin), SYD985 ([vic-]trastuzumab duocarmazine), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab, Oral Paclitaxel + Encequidar (Oraxol); Dostarlimab (TSR-042); Trastuzumab (Herceptin), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab, Amcenestrant, SAR439859, Amcenestrant + Abemaciclib, Amcenestrant (SAR439859), Abemaciclib (Verzenio), Amcenestrant + Letrozole, Amcenestrant (SAR439859), Letrozole (Femara), ARX788, ARX788 + Cemiplimab, VV1 + Cemiplimab, VOYAGER V1™, VSV-IFNβ-NIS, Datopotamab deruxtecan, Dato-DXd, Datopotamab deruxtecan + Durvalumab, Zanidatamab, Lasofoxifene, Z-endoxifen, ARV-471, ARV-471 + Letrozole, ARV-471 + Abemaciclib, Endoxifen + Abemaciclib, Rilvegostomig + TDXd, Dan222 + Niraparib, Sarilumab + Cemiplimab + Paclitaxel
QuantumLeap Healthcare Collaborative
Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
12/30
12/31
NCT02927964: TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma

Completed
1/2
21
US
Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, PCI-32765, Radiation Therapy, Cancer Radiotherapy, Irradiate, Irradiated, Irradiation, RADIATION, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, TLR9 Agonist SD-101, ISS-ODN SD-101, SD-101
Robert Lowsky, Janssen, LP, National Cancer Institute (NCI), The Leukemia and Lymphoma Society, Rising Tide Foundation
Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma
05/23
05/23
PERIO-02, NCT05220722: Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors

Active, not recruiting
1/2
89
US
SD-101, Pembrolizumab, Keytruda, Nivolumab, Opdivo, Ipilimumab, Yervoy
TriSalus Life Sciences, Inc.
Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma
12/23
01/25
NCT03831295: SD-101 and BMS-986178 in Treating Patients With Advanced or Metastatic Solid Malignancies

Completed
1
12
US
Anti-OX40 Antibody BMS 986178, BMS 986178, BMS-986178, TLR9 Agonist SD-101, ISS-ODN SD-101, SD-101
Ronald Levy, Bristol-Myers Squibb
Advanced Malignant Solid Neoplasm, Extracranial Solid Neoplasm, Metastatic Malignant Solid Neoplasm
10/21
10/21
NCT04050085: SD-101, Nivolumab, and Radiation Therapy in Treating Patients With Chemotherapy-Refractory Metastatic Pancreatic Cancer

Completed
1
6
US
Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo, Radiation Therapy, Cancer Radiotherapy, Irradiate, Irradiated, irradiation, Radiation, Radiotherapeutics, RADIOTHERAPY, RT, Therapy, Radiation, TLR9 Agonist SD-101, ISS-ODN SD-101, SD-101
University of California, Davis, National Cancer Institute (NCI), Bristol-Myers Squibb, Dynavax Technologies Corporation
Metastatic Pancreatic Adenocarcinoma, Refractory Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
12/21
05/22
NCT03410901: TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas

Completed
1
14
US
Anti-OX40 Antibody BMS 986178, BMS 986178, BMS-986178, Laboratory Biomarker Analysis, Radiation Therapy, Cancer Radiotherapy, Irradiate, Irradiated, irradiation, RADIATION, Radiotherapeutics, radiotherapy, RT, Therapy, Radiation, TLR9 Agonist SD-101, ISS-ODN SD-101, SD-101
Ronald Levy, National Cancer Institute (NCI)
B-Cell Non-Hodgkin Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Small Lymphocytic Lymphoma
10/24
10/24
PERIO-01, NCT04935229: Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma

Hourglass Jul 2024 - Dec 2024 : P1 data from PERIO-01 trial for uveal melanoma liver metastases
Active, not recruiting
1
80
US
SD-101, Nivolumab, Opdivo, Ipilimumab, Yervoy, Nivolumab and Relatlimab, Opdualag
TriSalus Life Sciences, Inc.
Metastatic Uveal Melanoma in the Liver
09/24
01/25
PERIO-03, NCT05607953: Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma

Active, not recruiting
1
60
US
SD-101, anti-PD-1
TriSalus Life Sciences, Inc.
Locally Advanced Pancreatic Adenocarcinoma
09/27
10/27
NCT06710223: Cryoablation and Arterial Infusion of SD-101 in Combination with Durvalumab and Tremelimumab

Recruiting
1
20
US
SD-101, nelitolimod, Cryotherapy, Tremelimumab, Durvalumab
University of California, San Diego, TriSalus Life Sciences
Hepatocellular Carcinoma
06/27
06/27
MVC-COV1901 / National Institutes of Health, Medigen Biotech
NCT05079633: A Heterologous Prime-boost Study to Evaluate Immunogenicity and Safety of mRNA-1273 With MVC-COV1901 in Adults

Completed
4
220
RoW
Homologous boost schedule, Heterologous boost schedule
National Taiwan University Hospital
Covid19 Vaccine
10/21
01/23
NCT05097053: A Heterologous 3rd COVID-19 Vaccine of MVC-COV1901 to Evaluate Immunogenicity and Safety in Adults With ChAdOx1-nCov-19

Recruiting
4
200
RoW
MVC-COV1901(3 Months), MVC-COV1901(6 Months)
Taoyuan General Hospital, Medigen Vaccine Biologics Corp.
COVID-19 Vaccine
03/22
07/22
NCT05426343: A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Vaccine Compared With AZD1222

Completed
3
200
RoW
MVC-COV1901, AZD1222
Medigen Vaccine Biologics Corp.
COVID-19 Vaccine
10/22
01/23
NCT05198596: A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Compared With AZD1222 in Adults Aged 18 Years and Above

Completed
3
250
RoW
MVC-COV1901, AZD1222
Medigen Vaccine Biologics Corp.
COVID-19 Vaccine
11/22
03/23
NCT05197153: A Study to Evaluate the Safety and Immunogenicity of Booster With AZD1222, mRNA-1273, or MVC-COV1901 Against COVID-19

Completed
2
804
RoW
Half dose of MVC-COV1901, Full dose of MVC-COV1901, AZD1222, Half dose of mRNA-1273
Medigen Vaccine Biologics Corp., Coalition for Epidemic Preparedness Innovations
COVID-19 Vaccine
06/22
10/22
NCT05054621: Immunogenicity of COVID-19 Vaccine on Heterologous Schedule

Completed
2
100
RoW
Heterologous prime-boost schedule with AZD1222 and MVC-COV1901, Homologous prime-boost schedule with two doses of AZD1222
Chang Gung Memorial Hospital
Covid-19, Vaccine, Immunogenicity, Reactogenicity, Healthy
08/22
08/22
NCT05132855: The Immune Response of Heterologous Boost Third Dose of mRNA and Protein COVID-19 Vaccine

Active, not recruiting
1/2
340
RoW
BNT162b2, mRNA-1273, MVC-COV1901
Chang Gung Memorial Hospital, Medigen Vaccine Biologics Corp.
COVID-19, Breakthrough Infection
04/23
04/23
NCT05216601: A Study to Evaluate the Safety, Tolerability, and Immunogenicity of MVC-COV1901 or MVC-COV1901(Beta) Against COVID-19

Completed
1
107
RoW
MVC-COV1901, MVC-COV1901(Beta)-15, MVC-COV1901(Beta)-25
Medigen Vaccine Biologics Corp.
COVID-19 Vaccine
07/22
11/22
Covifenz (virus-like particles (VLP) of SARS-CoV-2 spike protein) / Mitsubishi Tanabe, Laval University, Dynavax, GSK
NCT05040789: Phase 3 Study to Evaluate the Lot Consistency of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine

Withdrawn
3
900
Canada
CoVLP formulation
Medicago
COVID-19
05/22
05/22
NCT04636697 / 2020-005576-35: Study of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults

Active, not recruiting
2/3
30918
Europe, Canada, US, RoW
Intramuscular injection, Intramuscular vaccine
Medicago
SARS-CoV-2 Infection
08/21
04/22
NCT04662697: Study of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults (USA)

Not yet recruiting
2
918
NA
Intramuscular injection, intramuscular accine
Medicago
SARS-CoV-2 Infection
12/21
03/22
MOSAIC, NCT04894435: Mix and Match of the COVID-19 Vaccine for Safety and Immunogenicity

Active, not recruiting
2
669
Canada
mRNA-1273 SARS-CoV-2 vaccine, COVID-19 Vaccine Moderna, Spikevax, BNT162b2, Pfizer-BioNTech COVID-19 Vaccine, Comirnaty, ChAdOx1-S [recombinant], Astra Zeneca COVID-19 Vaccine, COVISHIELD AstraZeneca COVID-19 Vaccine, Vaxzevria, 0, 28 day schedule, 0, 112 day schedule, Covifenz, Medicago COVID-19 vaccine
Canadian Immunization Research Network, Canadian Center for Vaccinology, BC Children's Hospital Research Institute, Children's Hospital Research Institute of Manitoba, CHU de Quebec-Universite Laval, Ottawa Hospital Research Institute, Ontario Agency for Health Protection and Promotion, University of Toronto, Massachusetts General Hospital, Interior Health, McGill University Health Centre/Research Institute of the McGill University Health Centre
COVID-19
11/24
08/25
NCT05065619: Safety Immunogenicity Study of MT-2766 in Japanese Adults（COVID-19）

Terminated
1/2
128
Japan
MT-2766 High dose (3.75 µg), CoVLP, AS03 adjuvant, Placebo, MT-2766 Low dose
Medicago, Mitsubishi Tanabe Pharma Corporation
SARS-CoV-2 Infection
03/22
01/23
SCB-2019 / Sichuan Clover Biopharma
NCT05470803: An Observer-blind, Cohort Randomized, Exploratory Phase 3 Study to Evaluate the Safety and Immunogenicity of Recombinant Covid-19 Vaccine, mRNA Covid-19 Vaccine and Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine as 4th Dose in Individuals Primed/ Boosted With Various Regimens

Not yet recruiting
3
360
RoW
AstraZeneca/Fiocruz, Pfizer/Wyeth, Clover SCB-2019
D'Or Institute for Research and Education, Bill and Melinda Gates Foundation, University of Oxford
COVID-19
12/22
08/23
NCT05812586: Assessment of Immunogenicity, Safety and Reactogenicity of a Booster Dose of Various COVID-19 Vaccine Platforms in Individuals Primed With Several Regimes.

Active, not recruiting
3
760
RoW
SCB-2019/Clover, AstraZeneca/Fiocruz, Pfizer/Wyeth
D'Or Institute for Research and Education, Bill and Melinda Gates Foundation
COVID-19
06/23
09/23
NCT05188677: Immunogenicity and Safety Study of SCB-2019 Vaccine as a Booster to COVID-19 Vaccine in Adults

Completed
3
1831
RoW
Candidate vaccine, SCB-2019, Comirnaty Vaccine, Vaxzevria Vaccine, CoronaVac Vaccine
Clover Biopharmaceuticals AUS Pty Ltd
COVID-19
06/23
06/23
NCT05926440: Immunogenicity and Safety Study of SCB-2023 Vaccine as a Booster in Adults

Withdrawn
3
600
RoW
SCB-2023 vaccine (trivalent), a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19; intramuscular injection, SCB-2019 (monovalent), a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19; intramuscular injection
Clover Biopharmaceuticals AUS Pty Ltd
COVID-19
08/23
08/23
NCT06567457: Immunogenicity and Safety Study of Monovalent Omicron XBB.1.5 Vaccine as a Booster in Adults

Withdrawn
3
NA
SCB-2023B vaccine, a monovalent Omicron XBB.1.5 recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19, SCB-2019 vaccine, a monovalent wu-hu1 SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19
Clover Biopharmaceuticals AUS Pty Ltd
COVID-19
09/24
10/24
SPECTRA, NCT04672395 / 2020-004272-17: A Controlled Phase 2/3 Study of Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Vaccine (SCB-2019) for the Prevention of COVID-19

Completed
2/3
31454
Europe, RoW
CpG 1018/Alum-adjuvanted SCB-2019 vaccine, Placebo; 0.9% saline, SCB-2019 vaccine, SCB-2019 vaccine for Placebo
Clover Biopharmaceuticals AUS Pty Ltd, Coalition for Epidemic Preparedness Innovations, International Vaccine Institute
COVID-19
09/22
04/23
NCT05193279: Safety and Immunogenicity of SCB-2019 in Children <18 Years of Age

Withdrawn
2/3
3820
RoW
Candidate vaccine, SCB-2019
Clover Biopharmaceuticals AUS Pty Ltd
COVID-19
12/22
12/22
2020-004272-17: A controlled Phase 2/3 study of adjuvanted recombinant SARS-CoV-2 trimeric S-protein vaccine (SCB-2019) for the prevention of COVID-19

Not yet recruiting
2/3
30000
Europe
SCB-2019 (CpG 1018/Alum-djuvanted SCB-2019), SCB-2019, Solution for injection
Clover Biopharmaceuticals AUS Pty Ltd, Clover Biopharmaceuticals AUS Pty Ltd
SARS-CoV-2-mediated COVID-19, COVID-19 and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, Diseases [C] - Virus Diseases [C02]
 
 
NCT04954131: Immunogenicity and Safety Study of Adjuvanted SARS-CoV-2 (SCB-2019) Vaccine in Adultsin China

Active, not recruiting
2
766
RoW
Candidate Vaccine, SCB-2019, Placebo
Zhejiang Clover Biopharmaceuticals, Inc.
COVID-19
11/21
11/22
TP-SCB-2019001, NCT05087368: Immunogenicity and Safety of Heterologous and Homologous Boosting With ChAdOx1-S and CoronaVac or a Formulation of SCB-2019 (COVID-19)

Not yet recruiting
2
520
RoW
ChAdOx1-S COVID-19 Vaccine(Fiocruz/Oxford-AstraZeneca), CoronaVac (Sinovac Biotech), Adjuvanted Recombinant SARS-CoV-2 TrimericS-protein Subunit Vaccine (SCB-2019 - Clover)
D'Or Institute for Research and Education, Bill and Melinda Gates Foundation, Instituto Fernandes Figueira
Covid19
04/22
04/22
NCT05228314: Safety and Immunogenicity Dose-finding Study of Adjuvanted SCB-2020S Vaccine in Adults

Completed
1
153
RoW
Candidate vaccine, SCB-2020S, Candidate vaccine, SCB-2019, Squalene based adjuvant, CpG/alum adjuvant
Clover Biopharmaceuticals AUS Pty Ltd
COVID-19
09/22
04/23
VLA 2001 / Valneva
COV-COMPARE, NCT04864561: Immunogenicity of Vaccine VLA2001 Compared to AZD1222

Completed
3
4034
Europe
VLA2001, AZD1222, VLA2001 - adolescent part, Placebo
Valneva Austria GmbH
SARS-CoV-2 Virus Infection
07/21
03/23
NCT04956224: Safety and Immunogenicity of VLA2001 Adults Aged ≥56 Years

Completed
3
306
RoW
VLA2001
Valneva Austria GmbH
SARS-CoV-2 Virus Infection
11/21
11/22
NCT05545683: Safety and Immunogenicity of Inactivated Heterologous Booster Vaccination

Withdrawn
3
100
RoW
VLA 2001
Centro de Estudios en Infectogía Pediatrica
COVID-19
03/23
06/24
2022-000035-23: Immune response of VLA2001 Booster vaccine in adults who received mRNA COVID-19 vaccines, have been SARS-CoV-2 naturally infected or had a combination of both

Not yet recruiting
2/3
178
Europe
VLA2001, VLA2001, Suspension for injection
Valneva Austria GmbH, Valneva Austria GmbH
Coronavirus disease (COVID-19) is an infectious disease caused by a newly discovered coronavirus.Most people infected with the COVID-19 virus will experience mild to moderate respiratory illness and recover without requiring special treatment. Older people, and those with underlying medical problems like cardiovascular disease, diabetes, chronic respiratory disease, and cancer are more likely to develop serious illness., COVID-19 is an illness caused by a new coronavirus that can spread from person to person. COVID-19 symptoms can range from mild (or no symptoms) to severe illness, Diseases [C] - Virus Diseases [C02]
 
 
NCT05364242 / 2022-000035-23: VLA2001 Booster in Adult Participants After Priming With mRNA COVID-19 Vaccine and/or Natural SARS-CoV-2 Infection

Completed
2/3
178
Europe, RoW
VLA2001
Valneva Austria GmbH, Valneva Austria GmbH
SARS-CoV-2 Infection
09/22
05/23
RBD SARS-CoV-2 HBsAg VLP Vaccine / SpyBiotech, Serum Institute of India, Dynavax
ACTRN12620001308987: A Phase 1/2 randomized, placebo-controlled, multi-centre study to evaluate the safety and immunogenicity of a novel Receptor Binding Domain (RBD) COVID-19 Vaccine in Healthy Adults

Terminated
1/2
255
 
Accelagen Pty Ltd, Serum Institute of India Pvt Ltd
SARS-CoV-2, COVID-19
 
 
tetanus/diphtheria/pertussis booster vaccine (Tdap-1018) / Dynavax
ACTRN12620001177943p: A study to evaluate the safety and tolerability of Tetanus/Diptheria/Pertussis Booster Vaccine compared to a licensed Tdap vaccine in Healthy Volunteers between 10 - 22 years of age

Not yet recruiting
1
274
 
Dynavax Technologies Corporation, Dynavax Technologies Corporation
Pertussis; Diptheria; Tetanus
 
 
ACTRN12620001177943: A study to evaluate the Safety, Tolerability, and Immunogenicity of an Investigational Tetanus/Diphtheria/Pertussis Booster Vaccine (Tdap-1018) Compared to Boostrix in Healthy Volunteers Between 10 and 22 Years of Age

Completed
1
138
 
Dynavax Technologies Corporation, Dynavax Technologies Corporation
Pertussis, Diptheria, Tetanus
 
 
ACTRN12624000233527: Extension study of DV2-TDAP-01 to assess immunogenicity of Tdap-1018 to pertussis antigens.

Completed
N/A
57
 
Dynavax Technologies Corporation, Dynavax Technologies Corporation
Pertussis, Diptheria, Tetanus
 
 
adjuvant CpG 1018 / Dynavax
NCT05433285: Immuno-bridging Study of COVID-19 Protein Subunit Recombinant Vaccine

Completed
3
4050
RoW
COVID-19 Protein Subunit Recombinant Vaccine, Active Comparator
PT Bio Farma, Fakultas Kedokteran Universitas Indonesia, Faculty of Medicine Universitas Diponegoro, Faculty of Medicine Universitas Andalas, Faculty of Medicine Universitas Hassanudin
COVID-19
08/22
08/23
NCT05313035: Safety and Immunogenicity Study of COVID-19 Protein Subunit Recombinant Vaccine

Completed
2/3
360
RoW
SARS-CoV-2 protein subunit recombinant vaccine, placebo
PT Bio Farma, Faculty of Medicine, Universitas Indonesia, Jakarta, Faculty of Medicine, Diponegoro University, Semarang, Faculty of Medicine, Universitas Andalas, Padang, Faculty of Medicine, Universitas Hassanudin, Makassar
COVID-19
07/22
02/23
NCT05506969: Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine With CpG 1018® Adjuvant Compared With rF1V Vaccine in Adults 18 to 55 Years of Age

Completed
2
200
US
rF1V vaccine and CpG 1018® adjuvant, rF1V vaccine
Dynavax Technologies Corporation, United States Department of Defense
Plague, Pneumonic, Plague, Vaccine-Preventable Diseases
10/23
04/24
NCT06851832: Clinical Trial of Recombinant Herpes Zoster Vaccine (CHO Cell) in Healthy Chinese Population Aged 40 Years and Older

Recruiting
1/2
960
RoW
Recombinant zoster vaccine(CHO cell)(low adjuvant), Recombinant Zoster Vaccine (CHO cell), Zoster Vaccine, Live, Recombinant Zoster Vaccine (CHO cell) (Adjuvant control), Normal Saline
Ab&B Bio-tech Co., Ltd.JS, Yither Biotechnology Co., Ltd
Herpes Zoster, Herpes Zoster Vaccine
09/26
09/28
NCT05228613: Safety and Immunogenicity Study of COVID-19 Protein Subunit Recombinant Vaccine Adjuvanted With Alum+CpG 1018

Completed
1
175
RoW
SARS-CoV-2 protein subunit recombinant vaccine, SARS-CoV-2 inactivated vaccine
PT Bio Farma, Fakultas Kedokteran Universitas Indonesia, Faculty of Medicine, Diponegoro University, Semarang
COVID-19
08/22
01/23
NCT06541093: Study to Evaluate the Safety and Immunogenicity of an HIV-1 Vaccine Regimen of Adjuvanted UVAX-1107 Followed by Adjuvanted UVAX-1107 or Adjuvanted UVAX-1197 in Healthy Subjects Aged 25-55 Years.

Completed
1
34
RoW
UVAX-1107, UVAX-1197, Placebo
Uvax Bio LLC
AIDS/HIV - RelatedDisease Associated With AIDS, Vaccine-Preventable Diseases, HIV Infections
03/25
03/25
VLA1601-102, NCT06334393: Phase 1 Trial to Assess the Safety and Immunogenicity of an Inactivated, Adjuvanted Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Adults

Active, not recruiting
1
150
US
VLA1601, CpG 1018®, 3M-052-AF
Valneva Austria GmbH
Zika, Zika Virus Infection
05/25
04/26
ACTRN12624000064505: Study to evaluate the safety and immunogenicity of an HIV-1 vaccine regimen of adjuvanted UVAX-1107 followed by adjuvanted UVAX-1107 or adjuvanted UVAX-1197 in healthy subjects aged 25-55 years.

Active, not recruiting
1
34
 
Uvax Bio Australia, Pty, Ltd, a wholly owned subsidiary of Uvax Bio, LLC, UVAX Bio LLC
Acquired immune deficiency syndrome (AIDS / HIV)
 
 
NCT05606341: Innate Immunity Stimulation Via TLR9 in Early AD

Recruiting
1
15
US
CpG1018, Placebo
NYU Langone Health, Alzheimer's Association
Mild Cognitive Impairment, Alzheimer Dementia
11/25
11/25
NCT04177355: Evaluating the Safety and Immunogenicity of HIV-1 BG505 SOSIP.664 gp140 With TLR Agonist and/or Alum Adjuvants in Healthy, HIV-uninfected Adults

Completed
1
127
US
BG505 SOSIP.664 gp140, Placebo, 3M-052-AF, CpG 1018, GLA-LSQ, Alum (Aluminum Hydroxide Suspension), Trimer 4571
National Institute of Allergy and Infectious Diseases (NIAID), HIV Vaccine Trials Network, International AIDS Vaccine Initiative, Access to Advanced Health Institute (AAHI), Dynavax Technologies Corporation, Fred Hutchinson Cancer Center
HIV Infections
11/24
11/24
IndoVac (SARS-CoV-2 protein subunit recombinant vaccine) / Bio Farma Indonesia
NCT05546502: Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant Vaccine in Healthy Children

Completed
3
1050
RoW
SARS-CoV-2 Protein Subunit Recombinant Vaccine, Active Comparator
PT Bio Farma, Center for Child Health Universitas Gadjah Mada (CCH-PRO UGM, Cipto Mangunkusumo Hospital/Department of Child Health, Faculty of Medicine, University of Indonesia, Jakarta, Faculty of Medicine, Andalas University
Vaccine Reaction, Vaccine Adverse Reaction
12/23
01/24
NCT05525208: Booster Study of COVID-19 Protein Subunit Recombinant Vaccine

Completed
2
696
RoW
SARS-CoV-2 subunit protein recombinant vaccine, Active Comparator
PT Bio Farma, Universitas Padjadjaran, Udayana University
COVID-19
07/23
08/23
Z-1018 / Dynavax
NCT06569823: Safety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adults

Recruiting
1/2
440
RoW
Z-1018, Shingrix
Dynavax Technologies Corporation
Shingles, Herpes Zoster, Vaccine-Preventable Diseases
09/26
09/26
BG505 SOSIP.664 gp140/CpG 1018+alum / IAVI, National Institute of Allergy and Infectious Diseases, Dynavax
No trials found
rF1V vaccine with CpG 1018 / Dynavax, US Department of Defense
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
DV 1179 / Dynavax
DV1179a: Dynavax Reports Second Quarter 2014 Financial Results and Safety and Pharmacodynamic Results for Asthma and Lupus Drug Candidates

Checkmark
Aug 2014 - Aug 2014: 
Not yet recruiting
1b/2a
52
RoW
DV 1179
Dynavax
Lupus
 
 
300002: Proof-of-mechanism clinical trial of the TLR7 and TLR9 inhibitor, DV1179

Recruiting
1
0
RoW
DV 1179
Dynavax Technologies Corporation
systemic lupus erythematosus
 
 
Heplisav-B (hepatitis B vaccine (recombinant), adjuvanted) / Dynavax
NCT04588077 / 2020-001766-11: Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis

Recruiting
4
200
US
Heplisav-B Injectable Product, 2-dose regimen, 2-dose regimen, Heplisav-B Injectable Product, 3-dose regimen, 3-dose regimen
Mercy Medical Center
Hepatitis B, Cirrhosis, Liver, Chronic Liver Disease
07/24
07/24
NCT05170399: Vaccine Responses in Patients With B Cell Malignancies

Recruiting
4
500
US
Fluzone, Shingrix, Flucelvax, Afluria, PREVNAR 13, Heplisav -B, Pfizer-COVID-19 Vaccine, FluLaval, Fluarix, PNEUMOVAX 23, PREVNAR 20, AREXVY, ABRYSVO
National Heart, Lung, and Blood Institute (NHLBI)
Lymphoma
08/25
08/25
BEe-HIVe, NCT04193189: B-Enhancement of HBV Vaccination in Persons Living With HIV (): Evaluation of HEPLISAV-B

Completed
3
640
US, RoW
HEPLISAV-B, ENGERIX-B
National Institute of Allergy and Infectious Diseases (NIAID), Dynavax Technologies Corporation
HIV Infection, Hepatitis B
08/24
08/24
TherVacB, NCT06513286: - A Heterologous Protein Prime/MVA Boost Therapeutic Hepatitis B Vaccine Candidate

Not yet recruiting
1/2
89
Europe
TherVacB (HEPLISAV B), TherVacB (HBsAg ± c-di-AMP)
Michael Hoelscher, Institute of Virology Helmholtz Zentrum München Trogerstraße 30 81675 Munich, Germany
Chronic Hepatitis B
12/26
12/26
NCT03934736: HEPLISAV-B® in Adults With End-Stage Renal Disease (ESRD) Undergoing Hemodialysis

Completed
1
119
US
HEPLISAV-B®
Dynavax Technologies Corporation
End Stage Renal Disease on Hemodialysis (Diagnosis)
10/20
09/21
NCT05727267: A Heterologous Protein Prime/MVA Boost Therapeutic Hepatitis B Vaccine Candidate

Recruiting
1
24
Europe
HEPLISAV B; TherVacB, TherVacB
Universitätsklinikum Hamburg-Eppendorf, German Center for Infection Research, Medical Biometry and Epidemiology_- Universitätsklinikum Hamburg Eppendorf, Helmholtz Zentrum München, The Fraunhofer-Gesellschaft, Institute of Virology Helmholtz Zentrum München (HMGU), LMU Klinikum
Chronic Hepatitis B
02/26
06/26
HBR2, NCT05791851: Heplisav-B Revaccination for Hepatitis B Vaccine Nonresponders

Completed
N/A
31
US
University of Maryland, Baltimore, Baltimore Veterans Affairs Medical Center
HIV Infections, Hepatitis B, Vaccine Response Impaired
06/22
06/22
NCT03664648: DV2-HBV-27: Observational Pregnancy Registry

Active, not recruiting
N/A
300
US
HEPLISAV-B
Dynavax Technologies Corporation, PPD, Part of Thermo Fisher Scientific
Pregnant
09/24
12/24
nelitolimod (SD-101) / TriSalus Life Sci, UT MD Anderson Cancer Center
NCT03007732: Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT

Checkmark Initation of trial of pembrolizumab alone or in combination with SD-101 for metastatic prostate cancer
Jun 2017 - Jun 2017: Initation of trial of pembrolizumab alone or in combination with SD-101 for metastatic prostate cancer
Completed
2
23
US
Pembrolizumab, MK-3475, Keytruda, SD-101, Toll-like receptor 9, Leuprolide acetate, Intermittent androgen deprivation therapy, Abiraterone Acetate, Prednisone, Stereotactic Body Radiation Therapy, SBRT
David Oh, Prostate Cancer Foundation, Merck Sharp & Dohme LLC, TriSalus Life Sciences, Inc.
Prostatic Neoplasms
03/25
03/25
I-SPY 2, NCT01042379: I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

Hourglass Jan 2023 - Dec 2023 : From P2 I-SPY 2 trial for invasive breast cancer
Checkmark Presentation of data from I-SPY trial for HR+/HER2- and TNBC breast cancer at SABCS 2022
Dec 2022 - Dec 2022: Presentation of data from I-SPY trial for HR+/HER2- and TNBC breast cancer at SABCS 2022
Checkmark Data from trial evaluating T-DM1+pertuzumab in the adjuvant setting
Nov 2018 - Nov 2018: Data from trial evaluating T-DM1+pertuzumab in the adjuvant setting
More
Recruiting
2
5000
US
Standard Therapy, Paclitaxel (Taxol); Doxorubicin (Adriamycin), AMG 386 with or without Trastuzumab, AMG 386 (Trebananib); (Trastuzumab) Herceptin, AMG 479 (Ganitumab) plus Metformin, Ganitumab, MK-2206 with or without Trastuzumab, (Trastuzumab) Herceptin, AMG 386 and Trastuzumab, AMG 386 (Trebananib); Trastuzumab (Herceptin), T-DM1 and Pertuzumab, T-DM1 (Trastuzumab emtansine); Pertuzumab (Perjeta), Pertuzumab and Trastuzumab, Pertuzumab (Perjeta); Trastuzumab (Herceptin), Ganetespib, ABT-888, Veliparib, Neratinib, PLX3397, Pembrolizumab - 4 cycle, Talazoparib plus Irinotecan, Patritumab and Trastuzumab, Pembrolizumab - 8 cycle, SGN-LIV1A, Durvalumab plus Olaparib, SD-101 + Pembrolizumab, Tucatinib plus trastuzumab and pertuzumab, Cemiplimab, Cemiplimab plus REGN3767, Trilaciclib with or without trastuzumab + pertuzumab, Trilaciclib (G1T28); Pertuzumab (Perjeta); Trastuzumab (Herceptin), SYD985 ([vic-]trastuzumab duocarmazine), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab, Oral Paclitaxel + Encequidar (Oraxol); Dostarlimab (TSR-042); Trastuzumab (Herceptin), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab, Amcenestrant, SAR439859, Amcenestrant + Abemaciclib, Amcenestrant (SAR439859), Abemaciclib (Verzenio), Amcenestrant + Letrozole, Amcenestrant (SAR439859), Letrozole (Femara), ARX788, ARX788 + Cemiplimab, VV1 + Cemiplimab, VOYAGER V1™, VSV-IFNβ-NIS, Datopotamab deruxtecan, Dato-DXd, Datopotamab deruxtecan + Durvalumab, Zanidatamab, Lasofoxifene, Z-endoxifen, ARV-471, ARV-471 + Letrozole, ARV-471 + Abemaciclib, Endoxifen + Abemaciclib, Rilvegostomig + TDXd, Dan222 + Niraparib, Sarilumab + Cemiplimab + Paclitaxel
QuantumLeap Healthcare Collaborative
Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
12/30
12/31
NCT02927964: TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma

Completed
1/2
21
US
Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, PCI-32765, Radiation Therapy, Cancer Radiotherapy, Irradiate, Irradiated, Irradiation, RADIATION, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, TLR9 Agonist SD-101, ISS-ODN SD-101, SD-101
Robert Lowsky, Janssen, LP, National Cancer Institute (NCI), The Leukemia and Lymphoma Society, Rising Tide Foundation
Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma
05/23
05/23
PERIO-02, NCT05220722: Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors

Active, not recruiting
1/2
89
US
SD-101, Pembrolizumab, Keytruda, Nivolumab, Opdivo, Ipilimumab, Yervoy
TriSalus Life Sciences, Inc.
Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma
12/23
01/25
NCT03831295: SD-101 and BMS-986178 in Treating Patients With Advanced or Metastatic Solid Malignancies

Completed
1
12
US
Anti-OX40 Antibody BMS 986178, BMS 986178, BMS-986178, TLR9 Agonist SD-101, ISS-ODN SD-101, SD-101
Ronald Levy, Bristol-Myers Squibb
Advanced Malignant Solid Neoplasm, Extracranial Solid Neoplasm, Metastatic Malignant Solid Neoplasm
10/21
10/21
NCT04050085: SD-101, Nivolumab, and Radiation Therapy in Treating Patients With Chemotherapy-Refractory Metastatic Pancreatic Cancer

Completed
1
6
US
Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo, Radiation Therapy, Cancer Radiotherapy, Irradiate, Irradiated, irradiation, Radiation, Radiotherapeutics, RADIOTHERAPY, RT, Therapy, Radiation, TLR9 Agonist SD-101, ISS-ODN SD-101, SD-101
University of California, Davis, National Cancer Institute (NCI), Bristol-Myers Squibb, Dynavax Technologies Corporation
Metastatic Pancreatic Adenocarcinoma, Refractory Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
12/21
05/22
NCT03410901: TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas

Completed
1
14
US
Anti-OX40 Antibody BMS 986178, BMS 986178, BMS-986178, Laboratory Biomarker Analysis, Radiation Therapy, Cancer Radiotherapy, Irradiate, Irradiated, irradiation, RADIATION, Radiotherapeutics, radiotherapy, RT, Therapy, Radiation, TLR9 Agonist SD-101, ISS-ODN SD-101, SD-101
Ronald Levy, National Cancer Institute (NCI)
B-Cell Non-Hodgkin Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Small Lymphocytic Lymphoma
10/24
10/24
PERIO-01, NCT04935229: Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma

Hourglass Jul 2024 - Dec 2024 : P1 data from PERIO-01 trial for uveal melanoma liver metastases
Active, not recruiting
1
80
US
SD-101, Nivolumab, Opdivo, Ipilimumab, Yervoy, Nivolumab and Relatlimab, Opdualag
TriSalus Life Sciences, Inc.
Metastatic Uveal Melanoma in the Liver
09/24
01/25
PERIO-03, NCT05607953: Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma

Active, not recruiting
1
60
US
SD-101, anti-PD-1
TriSalus Life Sciences, Inc.
Locally Advanced Pancreatic Adenocarcinoma
09/27
10/27
NCT06710223: Cryoablation and Arterial Infusion of SD-101 in Combination with Durvalumab and Tremelimumab

Recruiting
1
20
US
SD-101, nelitolimod, Cryotherapy, Tremelimumab, Durvalumab
University of California, San Diego, TriSalus Life Sciences
Hepatocellular Carcinoma
06/27
06/27
MVC-COV1901 / National Institutes of Health, Medigen Biotech
NCT05079633: A Heterologous Prime-boost Study to Evaluate Immunogenicity and Safety of mRNA-1273 With MVC-COV1901 in Adults

Completed
4
220
RoW
Homologous boost schedule, Heterologous boost schedule
National Taiwan University Hospital
Covid19 Vaccine
10/21
01/23
NCT05097053: A Heterologous 3rd COVID-19 Vaccine of MVC-COV1901 to Evaluate Immunogenicity and Safety in Adults With ChAdOx1-nCov-19

Recruiting
4
200
RoW
MVC-COV1901(3 Months), MVC-COV1901(6 Months)
Taoyuan General Hospital, Medigen Vaccine Biologics Corp.
COVID-19 Vaccine
03/22
07/22
NCT05426343: A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Vaccine Compared With AZD1222

Completed
3
200
RoW
MVC-COV1901, AZD1222
Medigen Vaccine Biologics Corp.
COVID-19 Vaccine
10/22
01/23
NCT05198596: A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Compared With AZD1222 in Adults Aged 18 Years and Above

Completed
3
250
RoW
MVC-COV1901, AZD1222
Medigen Vaccine Biologics Corp.
COVID-19 Vaccine
11/22
03/23
NCT05197153: A Study to Evaluate the Safety and Immunogenicity of Booster With AZD1222, mRNA-1273, or MVC-COV1901 Against COVID-19

Completed
2
804
RoW
Half dose of MVC-COV1901, Full dose of MVC-COV1901, AZD1222, Half dose of mRNA-1273
Medigen Vaccine Biologics Corp., Coalition for Epidemic Preparedness Innovations
COVID-19 Vaccine
06/22
10/22
NCT05054621: Immunogenicity of COVID-19 Vaccine on Heterologous Schedule

Completed
2
100
RoW
Heterologous prime-boost schedule with AZD1222 and MVC-COV1901, Homologous prime-boost schedule with two doses of AZD1222
Chang Gung Memorial Hospital
Covid-19, Vaccine, Immunogenicity, Reactogenicity, Healthy
08/22
08/22
NCT05132855: The Immune Response of Heterologous Boost Third Dose of mRNA and Protein COVID-19 Vaccine

Active, not recruiting
1/2
340
RoW
BNT162b2, mRNA-1273, MVC-COV1901
Chang Gung Memorial Hospital, Medigen Vaccine Biologics Corp.
COVID-19, Breakthrough Infection
04/23
04/23
NCT05216601: A Study to Evaluate the Safety, Tolerability, and Immunogenicity of MVC-COV1901 or MVC-COV1901(Beta) Against COVID-19

Completed
1
107
RoW
MVC-COV1901, MVC-COV1901(Beta)-15, MVC-COV1901(Beta)-25
Medigen Vaccine Biologics Corp.
COVID-19 Vaccine
07/22
11/22
Covifenz (virus-like particles (VLP) of SARS-CoV-2 spike protein) / Mitsubishi Tanabe, Laval University, Dynavax, GSK
NCT05040789: Phase 3 Study to Evaluate the Lot Consistency of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine

Withdrawn
3
900
Canada
CoVLP formulation
Medicago
COVID-19
05/22
05/22
NCT04636697 / 2020-005576-35: Study of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults

Active, not recruiting
2/3
30918
Europe, Canada, US, RoW
Intramuscular injection, Intramuscular vaccine
Medicago
SARS-CoV-2 Infection
08/21
04/22
NCT04662697: Study of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults (USA)

Not yet recruiting
2
918
NA
Intramuscular injection, intramuscular accine
Medicago
SARS-CoV-2 Infection
12/21
03/22
MOSAIC, NCT04894435: Mix and Match of the COVID-19 Vaccine for Safety and Immunogenicity

Active, not recruiting
2
669
Canada
mRNA-1273 SARS-CoV-2 vaccine, COVID-19 Vaccine Moderna, Spikevax, BNT162b2, Pfizer-BioNTech COVID-19 Vaccine, Comirnaty, ChAdOx1-S [recombinant], Astra Zeneca COVID-19 Vaccine, COVISHIELD AstraZeneca COVID-19 Vaccine, Vaxzevria, 0, 28 day schedule, 0, 112 day schedule, Covifenz, Medicago COVID-19 vaccine
Canadian Immunization Research Network, Canadian Center for Vaccinology, BC Children's Hospital Research Institute, Children's Hospital Research Institute of Manitoba, CHU de Quebec-Universite Laval, Ottawa Hospital Research Institute, Ontario Agency for Health Protection and Promotion, University of Toronto, Massachusetts General Hospital, Interior Health, McGill University Health Centre/Research Institute of the McGill University Health Centre
COVID-19
11/24
08/25
NCT05065619: Safety Immunogenicity Study of MT-2766 in Japanese Adults（COVID-19）

Terminated
1/2
128
Japan
MT-2766 High dose (3.75 µg), CoVLP, AS03 adjuvant, Placebo, MT-2766 Low dose
Medicago, Mitsubishi Tanabe Pharma Corporation
SARS-CoV-2 Infection
03/22
01/23
SCB-2019 / Sichuan Clover Biopharma
NCT05470803: An Observer-blind, Cohort Randomized, Exploratory Phase 3 Study to Evaluate the Safety and Immunogenicity of Recombinant Covid-19 Vaccine, mRNA Covid-19 Vaccine and Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine as 4th Dose in Individuals Primed/ Boosted With Various Regimens

Not yet recruiting
3
360
RoW
AstraZeneca/Fiocruz, Pfizer/Wyeth, Clover SCB-2019
D'Or Institute for Research and Education, Bill and Melinda Gates Foundation, University of Oxford
COVID-19
12/22
08/23
NCT05812586: Assessment of Immunogenicity, Safety and Reactogenicity of a Booster Dose of Various COVID-19 Vaccine Platforms in Individuals Primed With Several Regimes.

Active, not recruiting
3
760
RoW
SCB-2019/Clover, AstraZeneca/Fiocruz, Pfizer/Wyeth
D'Or Institute for Research and Education, Bill and Melinda Gates Foundation
COVID-19
06/23
09/23
NCT05188677: Immunogenicity and Safety Study of SCB-2019 Vaccine as a Booster to COVID-19 Vaccine in Adults

Completed
3
1831
RoW
Candidate vaccine, SCB-2019, Comirnaty Vaccine, Vaxzevria Vaccine, CoronaVac Vaccine
Clover Biopharmaceuticals AUS Pty Ltd
COVID-19
06/23
06/23
NCT05926440: Immunogenicity and Safety Study of SCB-2023 Vaccine as a Booster in Adults

Withdrawn
3
600
RoW
SCB-2023 vaccine (trivalent), a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19; intramuscular injection, SCB-2019 (monovalent), a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19; intramuscular injection
Clover Biopharmaceuticals AUS Pty Ltd
COVID-19
08/23
08/23
NCT06567457: Immunogenicity and Safety Study of Monovalent Omicron XBB.1.5 Vaccine as a Booster in Adults

Withdrawn
3
NA
SCB-2023B vaccine, a monovalent Omicron XBB.1.5 recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19, SCB-2019 vaccine, a monovalent wu-hu1 SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19
Clover Biopharmaceuticals AUS Pty Ltd
COVID-19
09/24
10/24
SPECTRA, NCT04672395 / 2020-004272-17: A Controlled Phase 2/3 Study of Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Vaccine (SCB-2019) for the Prevention of COVID-19

Completed
2/3
31454
Europe, RoW
CpG 1018/Alum-adjuvanted SCB-2019 vaccine, Placebo; 0.9% saline, SCB-2019 vaccine, SCB-2019 vaccine for Placebo
Clover Biopharmaceuticals AUS Pty Ltd, Coalition for Epidemic Preparedness Innovations, International Vaccine Institute
COVID-19
09/22
04/23
NCT05193279: Safety and Immunogenicity of SCB-2019 in Children <18 Years of Age

Withdrawn
2/3
3820
RoW
Candidate vaccine, SCB-2019
Clover Biopharmaceuticals AUS Pty Ltd
COVID-19
12/22
12/22
2020-004272-17: A controlled Phase 2/3 study of adjuvanted recombinant SARS-CoV-2 trimeric S-protein vaccine (SCB-2019) for the prevention of COVID-19

Not yet recruiting
2/3
30000
Europe
SCB-2019 (CpG 1018/Alum-djuvanted SCB-2019), SCB-2019, Solution for injection
Clover Biopharmaceuticals AUS Pty Ltd, Clover Biopharmaceuticals AUS Pty Ltd
SARS-CoV-2-mediated COVID-19, COVID-19 and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, Diseases [C] - Virus Diseases [C02]
 
 
NCT04954131: Immunogenicity and Safety Study of Adjuvanted SARS-CoV-2 (SCB-2019) Vaccine in Adultsin China

Active, not recruiting
2
766
RoW
Candidate Vaccine, SCB-2019, Placebo
Zhejiang Clover Biopharmaceuticals, Inc.
COVID-19
11/21
11/22
TP-SCB-2019001, NCT05087368: Immunogenicity and Safety of Heterologous and Homologous Boosting With ChAdOx1-S and CoronaVac or a Formulation of SCB-2019 (COVID-19)

Not yet recruiting
2
520
RoW
ChAdOx1-S COVID-19 Vaccine(Fiocruz/Oxford-AstraZeneca), CoronaVac (Sinovac Biotech), Adjuvanted Recombinant SARS-CoV-2 TrimericS-protein Subunit Vaccine (SCB-2019 - Clover)
D'Or Institute for Research and Education, Bill and Melinda Gates Foundation, Instituto Fernandes Figueira
Covid19
04/22
04/22
NCT05228314: Safety and Immunogenicity Dose-finding Study of Adjuvanted SCB-2020S Vaccine in Adults

Completed
1
153
RoW
Candidate vaccine, SCB-2020S, Candidate vaccine, SCB-2019, Squalene based adjuvant, CpG/alum adjuvant
Clover Biopharmaceuticals AUS Pty Ltd
COVID-19
09/22
04/23
VLA 2001 / Valneva
COV-COMPARE, NCT04864561: Immunogenicity of Vaccine VLA2001 Compared to AZD1222

Completed
3
4034
Europe
VLA2001, AZD1222, VLA2001 - adolescent part, Placebo
Valneva Austria GmbH
SARS-CoV-2 Virus Infection
07/21
03/23
NCT04956224: Safety and Immunogenicity of VLA2001 Adults Aged ≥56 Years

Completed
3
306
RoW
VLA2001
Valneva Austria GmbH
SARS-CoV-2 Virus Infection
11/21
11/22
NCT05545683: Safety and Immunogenicity of Inactivated Heterologous Booster Vaccination

Withdrawn
3
100
RoW
VLA 2001
Centro de Estudios en Infectogía Pediatrica
COVID-19
03/23
06/24
2022-000035-23: Immune response of VLA2001 Booster vaccine in adults who received mRNA COVID-19 vaccines, have been SARS-CoV-2 naturally infected or had a combination of both

Not yet recruiting
2/3
178
Europe
VLA2001, VLA2001, Suspension for injection
Valneva Austria GmbH, Valneva Austria GmbH
Coronavirus disease (COVID-19) is an infectious disease caused by a newly discovered coronavirus.Most people infected with the COVID-19 virus will experience mild to moderate respiratory illness and recover without requiring special treatment. Older people, and those with underlying medical problems like cardiovascular disease, diabetes, chronic respiratory disease, and cancer are more likely to develop serious illness., COVID-19 is an illness caused by a new coronavirus that can spread from person to person. COVID-19 symptoms can range from mild (or no symptoms) to severe illness, Diseases [C] - Virus Diseases [C02]
 
 
NCT05364242 / 2022-000035-23: VLA2001 Booster in Adult Participants After Priming With mRNA COVID-19 Vaccine and/or Natural SARS-CoV-2 Infection

Completed
2/3
178
Europe, RoW
VLA2001
Valneva Austria GmbH, Valneva Austria GmbH
SARS-CoV-2 Infection
09/22
05/23
RBD SARS-CoV-2 HBsAg VLP Vaccine / SpyBiotech, Serum Institute of India, Dynavax
ACTRN12620001308987: A Phase 1/2 randomized, placebo-controlled, multi-centre study to evaluate the safety and immunogenicity of a novel Receptor Binding Domain (RBD) COVID-19 Vaccine in Healthy Adults

Terminated
1/2
255
 
Accelagen Pty Ltd, Serum Institute of India Pvt Ltd
SARS-CoV-2, COVID-19
 
 
tetanus/diphtheria/pertussis booster vaccine (Tdap-1018) / Dynavax
ACTRN12620001177943p: A study to evaluate the safety and tolerability of Tetanus/Diptheria/Pertussis Booster Vaccine compared to a licensed Tdap vaccine in Healthy Volunteers between 10 - 22 years of age

Not yet recruiting
1
274
 
Dynavax Technologies Corporation, Dynavax Technologies Corporation
Pertussis; Diptheria; Tetanus
 
 
ACTRN12620001177943: A study to evaluate the Safety, Tolerability, and Immunogenicity of an Investigational Tetanus/Diphtheria/Pertussis Booster Vaccine (Tdap-1018) Compared to Boostrix in Healthy Volunteers Between 10 and 22 Years of Age

Completed
1
138
 
Dynavax Technologies Corporation, Dynavax Technologies Corporation
Pertussis, Diptheria, Tetanus
 
 
ACTRN12624000233527: Extension study of DV2-TDAP-01 to assess immunogenicity of Tdap-1018 to pertussis antigens.

Completed
N/A
57
 
Dynavax Technologies Corporation, Dynavax Technologies Corporation
Pertussis, Diptheria, Tetanus
 
 
adjuvant CpG 1018 / Dynavax
NCT05433285: Immuno-bridging Study of COVID-19 Protein Subunit Recombinant Vaccine

Completed
3
4050
RoW
COVID-19 Protein Subunit Recombinant Vaccine, Active Comparator
PT Bio Farma, Fakultas Kedokteran Universitas Indonesia, Faculty of Medicine Universitas Diponegoro, Faculty of Medicine Universitas Andalas, Faculty of Medicine Universitas Hassanudin
COVID-19
08/22
08/23
NCT05313035: Safety and Immunogenicity Study of COVID-19 Protein Subunit Recombinant Vaccine

Completed
2/3
360
RoW
SARS-CoV-2 protein subunit recombinant vaccine, placebo
PT Bio Farma, Faculty of Medicine, Universitas Indonesia, Jakarta, Faculty of Medicine, Diponegoro University, Semarang, Faculty of Medicine, Universitas Andalas, Padang, Faculty of Medicine, Universitas Hassanudin, Makassar
COVID-19
07/22
02/23
NCT05506969: Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine With CpG 1018® Adjuvant Compared With rF1V Vaccine in Adults 18 to 55 Years of Age

Completed
2
200
US
rF1V vaccine and CpG 1018® adjuvant, rF1V vaccine
Dynavax Technologies Corporation, United States Department of Defense
Plague, Pneumonic, Plague, Vaccine-Preventable Diseases
10/23
04/24
NCT06851832: Clinical Trial of Recombinant Herpes Zoster Vaccine (CHO Cell) in Healthy Chinese Population Aged 40 Years and Older

Recruiting
1/2
960
RoW
Recombinant zoster vaccine(CHO cell)(low adjuvant), Recombinant Zoster Vaccine (CHO cell), Zoster Vaccine, Live, Recombinant Zoster Vaccine (CHO cell) (Adjuvant control), Normal Saline
Ab&B Bio-tech Co., Ltd.JS, Yither Biotechnology Co., Ltd
Herpes Zoster, Herpes Zoster Vaccine
09/26
09/28
NCT05228613: Safety and Immunogenicity Study of COVID-19 Protein Subunit Recombinant Vaccine Adjuvanted With Alum+CpG 1018

Completed
1
175
RoW
SARS-CoV-2 protein subunit recombinant vaccine, SARS-CoV-2 inactivated vaccine
PT Bio Farma, Fakultas Kedokteran Universitas Indonesia, Faculty of Medicine, Diponegoro University, Semarang
COVID-19
08/22
01/23
NCT06541093: Study to Evaluate the Safety and Immunogenicity of an HIV-1 Vaccine Regimen of Adjuvanted UVAX-1107 Followed by Adjuvanted UVAX-1107 or Adjuvanted UVAX-1197 in Healthy Subjects Aged 25-55 Years.

Completed
1
34
RoW
UVAX-1107, UVAX-1197, Placebo
Uvax Bio LLC
AIDS/HIV - RelatedDisease Associated With AIDS, Vaccine-Preventable Diseases, HIV Infections
03/25
03/25
VLA1601-102, NCT06334393: Phase 1 Trial to Assess the Safety and Immunogenicity of an Inactivated, Adjuvanted Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Adults

Active, not recruiting
1
150
US
VLA1601, CpG 1018®, 3M-052-AF
Valneva Austria GmbH
Zika, Zika Virus Infection
05/25
04/26
ACTRN12624000064505: Study to evaluate the safety and immunogenicity of an HIV-1 vaccine regimen of adjuvanted UVAX-1107 followed by adjuvanted UVAX-1107 or adjuvanted UVAX-1197 in healthy subjects aged 25-55 years.

Active, not recruiting
1
34
 
Uvax Bio Australia, Pty, Ltd, a wholly owned subsidiary of Uvax Bio, LLC, UVAX Bio LLC
Acquired immune deficiency syndrome (AIDS / HIV)
 
 
NCT05606341: Innate Immunity Stimulation Via TLR9 in Early AD

Recruiting
1
15
US
CpG1018, Placebo
NYU Langone Health, Alzheimer's Association
Mild Cognitive Impairment, Alzheimer Dementia
11/25
11/25
NCT04177355: Evaluating the Safety and Immunogenicity of HIV-1 BG505 SOSIP.664 gp140 With TLR Agonist and/or Alum Adjuvants in Healthy, HIV-uninfected Adults

Completed
1
127
US
BG505 SOSIP.664 gp140, Placebo, 3M-052-AF, CpG 1018, GLA-LSQ, Alum (Aluminum Hydroxide Suspension), Trimer 4571
National Institute of Allergy and Infectious Diseases (NIAID), HIV Vaccine Trials Network, International AIDS Vaccine Initiative, Access to Advanced Health Institute (AAHI), Dynavax Technologies Corporation, Fred Hutchinson Cancer Center
HIV Infections
11/24
11/24
IndoVac (SARS-CoV-2 protein subunit recombinant vaccine) / Bio Farma Indonesia
NCT05546502: Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant Vaccine in Healthy Children

Completed
3
1050
RoW
SARS-CoV-2 Protein Subunit Recombinant Vaccine, Active Comparator
PT Bio Farma, Center for Child Health Universitas Gadjah Mada (CCH-PRO UGM, Cipto Mangunkusumo Hospital/Department of Child Health, Faculty of Medicine, University of Indonesia, Jakarta, Faculty of Medicine, Andalas University
Vaccine Reaction, Vaccine Adverse Reaction
12/23
01/24
NCT05525208: Booster Study of COVID-19 Protein Subunit Recombinant Vaccine

Completed
2
696
RoW
SARS-CoV-2 subunit protein recombinant vaccine, Active Comparator
PT Bio Farma, Universitas Padjadjaran, Udayana University
COVID-19
07/23
08/23
Z-1018 / Dynavax
NCT06569823: Safety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adults

Recruiting
1/2
440
RoW
Z-1018, Shingrix
Dynavax Technologies Corporation
Shingles, Herpes Zoster, Vaccine-Preventable Diseases
09/26
09/26
BG505 SOSIP.664 gp140/CpG 1018+alum / IAVI, National Institute of Allergy and Infectious Diseases, Dynavax
No trials found
rF1V vaccine with CpG 1018 / Dynavax, US Department of Defense
No trials found

Download Options